We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $754M
1-Year Est. Return 60.05%
This Fund
S&P 500
This Quarter Est. Return
+9.15%
1 Year Est. Return
+60.05%
3 Year Est. Return
+108.28%
5 Year Est. Return
+118.76%
10 Year Est. Return
+308.24%
AUM
$630M
AUM Growth
+$19.1M
Cap. Flow
-$22.7M
Cap. Flow %
-3.61%
Top 10 Hldgs %
32.12%
Holding
186
New
13
Increased
53
Reduced
79
Closed
17

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$4.6M
2
LOW icon
Lowe's Companies
LOW
+$4.54M
3
GNRC icon
Generac Holdings
GNRC
+$4.05M
4
ZBH icon
Zimmer Biomet
ZBH
+$3.64M
5
CHWY icon
Chewy
CHWY
+$2.07M

Sector Composition

Rank Sector Weight
1 Technology 30.19%
2 Healthcare 17.08%
3 Industrials 16.64%
4 Utilities 9.87%
5 Energy 6.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TT icon
176
Trane Technologies
TT
$106B
-12,150
Closed -$2.47M
VOD icon
177
Vodafone
VOD
$37.4B
-39,100
Closed -$371K
AGR
178
DELISTED
Avangrid, Inc.
AGR
-81,110
Closed -$2.45M
VMW
179
DELISTED
VMware, Inc
VMW
-41,350
Closed -$6.88M
HZNP
180
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
-78,762
Closed -$9.11M

Similar funds

John G. Ullman & Associates's Q4 2023 Portfolio in Review

As of Q4 2023, John G. Ullman & Associates held 186 positions worth $630M, up 3.1% from $611M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

John G. Ullman & Associates withdrew a net $22.7M in Q4 2023, closing 17 positions and reducing 79 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $9.11M position sold in full.

By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 28% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, John G. Ullman & Associates opened a new position in Lowe's Companies worth $4.98M.

  • John G. Ullman & Associates's largest Q4 2023 buy was Lowe's Companies: 22,375 shares worth $4.98M.
  • John G. Ullman & Associates added most to Broadcom in Q4 2023, an estimated $4.6M increase.
  • John G. Ullman & Associates's biggest Q4 2023 reduction was Aecom, cutting an estimated $6.65M.
  • John G. Ullman & Associates fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $9.11M.
  • John G. Ullman & Associates's ten largest holdings make up 32% of its $630M portfolio in Q4 2023.
  • John G. Ullman & Associates opened 13 new positions and closed 17 in Q4 2023.
  • John G. Ullman & Associates's portfolio value rose 3.1% quarter-over-quarter to $630M.

Based on John G. Ullman & Associates's 13F filing for Q4 2023, filed 31 Jan 2024.